Company Analysis

BiomX Inc. (PHGE)

NYSE: PHGE · Biological Products, (No Diagnostic Substances) · Dover, DE · filing with the SEC since 2018
Grade5.2
◀ Past 4.2● Present 5.0▶ Future 6.0
8 est.
The companyfiscal 2025, as filed
Revenuen/a
Net income-$36.2M-104.2%
Earnings per share$22.19-61.9%
Operating cash flow-$26.4M+28.6%
Cash$4.4M-74.1%
Debtn/a
Shareholders’ equity-$1.3M-105.4%
Shares, dilutedn/a
Return on equityn/a
The recordfrom its filings
Filings in 202693
Newest filingOct 23 · 8-K
Annual reportFeb 19, 2026
Quarterly reportAug 19, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$8.3M
Insider buys, 12 months$0.00
Patents granted2
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$45.5MCash from operations -$18.2Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
1819202122232425
As filed, in USD. Nothing here is a forecast.

News

Oct 23, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 19, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 13, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 8, 2026 · SEC EDGAR · Form DEFA14A
Extra proxy material
Open the filing on sec.gov
Oct 8, 2026 · SEC EDGAR · Form DEFA14A
Extra proxy material
Open the filing on sec.gov
Oct 7, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 6, 2026 · SEC EDGAR · Form DEF 14A
Proxy statement
Open the filing on sec.gov
Oct 5, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Oct 5, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton PHGE · research, not advice